Epidermodysplasia Verruciformis: Definition, Causes, and Clinical Manifestations
What is Epidermodysplasia Verruciformis?
Epidermodysplasia verruciformis (EV) constitutes a rare hereditary skin disorder, characterized by an affliction autosomal recessive. This condition manifests through a chronic rash of plaques brown color.
It is essential to note that a similar condition, called acquired epidermodysplasia verruciformis, can develop in patients presenting with a compromised immune system.
What are the Causes of Epidermodysplasia Verruciformis?
Each patch of epidermodysplasia verruciformis is caused by secondary with a specific subtype of the human papillomavirus (HPV).
HPV comprises numerous subtypes that can generate a wide spectrum of viral warts. While certain HPV subtypes have minimal or no clinical impact on the general population, these same subtypes trigger the characteristic clinical manifestations of epidermodysplasia verruciformis in individuals with a diminished immune response to the virus. To date, more than 30 HPV subtypes implicated in this pathology have been identified.
Who Develops Epidermodysplasia Verruciformis?
Epidermodysplasia verruciformis typically presents as a hereditary disorder autosomal recessive, which implies that the individual inherits an gene abnormal EV gene from each parent. Around 10% of patients diagnosed with epidermodysplasia verruciformis have parents who are consanguineous, meaning they share a common ancestor. Nevertheless, in some cases, sex-linked and autosomal dominant inheritance patterns have also been documented. sex y autosomal dominant.
The underlying cause frequently lies in mutations located in the genes EVER1 o EVER2, located on chromosome chromosome 17q25. This , originating from a compromises the cells' ability to control Unlike other infections by HPV. When these specific mutations are not present, other causes have been associated, such as mutations in the homologous gene of the RAS (family (RHOH), MST1 deficiency, and deficiencies in the splicing of the gene encoding LCK (lymphocyte-specificT lymphocytes kinase).
Generally, topical lesions Generally, the lesions begin to manifest during childhood and tend to persist persist. Data indicate that approximately 7.5% of cases appear in early childhood, 61.5% are diagnosed between ages 5 and 11, and 22.5% emerge during puberty. The disease impacts men and women equally, affecting people of all ethnicities.
The acquired variant of epidermodysplasia verruciformis develops as a consequence of HIV infection, an organ transplant, or the presence of a HIV, a transplantation lymphoma. lymphoma.
What are the Clinical Characteristics of Epidermodysplasia Verruciformis?
In the context of epidermodysplasia verruciformis, two main clinical presentations have been identified in patients:
- Papules and flat-surfaced plaques with papillomas., varying in color from white, pink, reddish-brown, dark brown to violet.
If you or someone you know presents with persistent and abnormal skin lesions, it is crucial to seek specialized medical evaluation to confirm the diagnosis and manage the risks associated with this unusual condition.
- Flat, superficial, and irregular lesions.
- Verrucous o seborrheic seborrheic keratosisWarty or seborrheic keratosis-like lesions. These are raised and warty brown in color. verrucous.
The warts appear in irregular clusters, ranging from a few to more than one hundred lesions. They are particularly predominant predominant in sun-exposed areas, such as hands, feet, face, and earlobes. Similar plaque-like lesions plaque usually manifest on the trunk, neck, arms, and legs. The palms, soles of the feet, armpits, and external genitalia can also be affected.
Complications of Epidermodysplasia Verruciformis
A fundamental concern for patients with epidermodysplasia verruciformis epidermodysplasia verruciformis is that between 30% and 60% of them may develop skin cancers from these lesions. These are mostly cutaneous squamous cell carcinoma and intraepidermal squamous cell carcinoma. carcinoma scaly cutaneous Basal cell carcinoma intraepidermal. and adnexal tumors cell are less frequent. Malignant tumors , invasive extension into the deep are malignant usually diagnosed in patients between 30 and 50 years old.
More than 90% of EV-associated skin cancers contain HPV types 5, 8, 10, and 47. EV lesions caused by HPV types 14, 20, 21, and 25 tend to remain benign. benign. Exposure to sunlight or ultraviolet radiation ultraviolet radiation increases the probability that a benign wart will evolve cancer cancer.
into skin cancer.
Aspects of the Diagnosis of Epidermodysplasia Verruciformis biopsy The diagnosis of epidermodysplasia verruciformis is generally established clinically. This condition is suspected upon the presence of a large number of viral warts that are resistant to usual treatments. A skin pathology biopsy may reveal distinctive histopathological features (see epidermodysplasia verruciformis pathology).
Some specialized laboratories offer the capability to identify the HPV subtype via polymerase chain reaction (PCR). polymerase chain reaction (PCR).
Treatment and Management of Epidermodysplasia Verruciformis
Epidermodysplasia Verruciformis Epidermodysplasia verruciformis is a chronic, lifelong condition. While active lesions can be treated or removed as they arise, the development of new lesions is expected to continue throughout the patient's life.
Currently, there is no cure that prevents the appearance of new lesions. Effective management of EV requires a combined approach including medical and surgical treatments, as well as counseling, continuous education, and periodic patient surveillance (especially if immunocompromised). immunocompromised).
- It is crucial to emphasize strict adherence to sun protection strategies, especially for those residing at high altitudes or working outdoors. Exposure to both UVB and UVA sunlight has been confirmed to increase the transformation rate of EV lesions into skin cancers.
- Encourage smoking cessation Encourage smoking cessation.
- Treat and eliminate lesions using methods analogous to those employed for other viral warts, such as chemical treatment, cryotherapy, electrosurgery, or laser ablation., cryotherapy, electrocirugía o ablation with laser.
- Oral and topical Topical retinoids topical (isotretinoin and acitretin), as well as fluorouracil and imiquimod, may be beneficial.
- Novel therapies under investigation for epidermodysplasia verruciformis epidermodysplasia verruciformis and its associated tumors include intralesional interferon, the combination of isotretinoin with interferon alpha or analogs analogs of cholecalciferol (Vitamin D).
- The Excision Surgical excision tumors.
